Mofo wraps up two life sciences buys

The London office of Morrison & Foerster (MoFo) has taken advantage of the M&A boom in life sciences, signing off two deals in one week. The firm acted for the buyer in one deal and the seller in the other.

MoFo corporate partner James Gubbins advised Oxford BioMedica on its purchase of Oxxon Therapeutics, while corporate partner Paul Claydon represented long-term client Paradigm Therapeutics on its sale to Japanese pharma giant Takeda Pharmaceutical Company.

WilmerHale acted for Oxxon and Allen & Overy advised Takeda. MoFo has been active in the life sciences sector over the past few months, advising Arrow on its sale to AstraZeneca and Tanox on its $919m (£465m) sale to Genentech.